DoD Peer Reviewed, Convergent Science Cancer Consortium Development Award — Defense Health Agency Contracting Activity - DHACA funding opportunity
Defense Health Agency Contracting Activity - DHACA · Federal agency

DoD Peer Reviewed, Convergent Science Cancer Consortium Development Award

The PRCRP seeks to promote novel approaches to ending cancer through convergent science cancer research. This effort will be executed through two separate award mechanisms, the Convergent Science Cancer Consortium Develo...

70
match
Deadline 1383 days ago Location Alabama Type grant Level Federal Closed posted Mar 31, 2022
✦ AI Summary
  • Who can apply: Federal-level applicants (see eligibility for details).
  • Funding amount: total funding pool ~$12,000,000.
  • Next deadline: September 7, 2022.
  • Issued by: Defense Health Agency Contracting Activity - DHACA.
How was this generated?

The “key facts” mode pulls structured fields directly from the official source posting (amount, deadline, eligibility tags). The AI mode adds a short plain-English narrative on top, generated from the same source. Always verify with the agency before applying.

AI-generated. Always verify with the official source.

Deadline
1383 days ago
Sep 7, 2022
Total pool
$12M

About this opportunity

The PRCRP seeks to promote novel approaches to ending cancer through convergent science cancer research. This effort will be executed through two separate award mechanisms, the Convergent Science Cancer Consortium Development Award in FY22 and the anticipated Convergent Science Cancer Consortium Award in FY24. Convergent science as defined by the National Science Foundation (https://www.nsf.gov/od/oia/convergence/index.jsp “is a means of solving vexing research problems, in particular, complex problems focusing on societal needs. It entails integrating expertise from different disciplines and forming novel frameworks to catalyze scientific discovery and innovation.” Convergent science taps into a variety of disciplines to answer the issues in cancer ( prevention, diagnosis/detection, treatment, quality of life) including but not limited to biomedical sciences, data chemistry. As a more holistic approach, convergent science offers patients the opportunity to fight cancer on various fronts beyond what is offered by multidisciplinary approaches by merging sciences together. Convergent science breaks down the barriers of cancer research and builds a whole answer with tools from different areas of expertise. Initiatives such as the Cancer Moonshot aim to decrease the death rate of cancer by 50% over the next 25 years and improve the experience of patients, their families, and caregivers. The goals set by initiatives such as the Cancer Moonshot require innovative and unique approaches to ending cancer. The FY22 Convergent Science Cancer Consortium Development Award and the anticipated FY24 Convergent Science Cancer Consortium Award answer the call to find ground-breaking ways through convergent science research to improve quality of life by decreasing the burden of cancer on Service Members, their the American public. The eligible applicants of the FY22 Convergent Science Cancer Consortium Development Award are expected to submit an application to compete for the Convergent Science Cancer Consortium Award anticipated to be offered in FY24. The PRCRP expects to fund three FY22 Convergent Science Cancer Consortium Development Awards, depending on the number and the quality of applications received. The PRCRP reserves the right to open the FY24 Convergent Science Cancer Consortium Award to all eligible applicants that meet the requirements of the anticipated FY24 Convergent Science Cancer Consortium Award, and/or to re-release the Convergent Science Cancer Consortium Development Award in FY24 if the goals of the FY22 Convergent Science Cancer Consortium Development Award are not met. Applications for the FY22 Convergent Science Cancer Consortium Development Award are being requested. The FY22 Convergent Science Cancer Consortium Development is a convergent science infrastructure and research mechanism that provides support to create a Coordinating Center, to establish the necessary collaborations, and to demonstrate the utility of convergent science in cancer science through its application in active research projects.

Funding agency

Tags

Want help applying?

Our specialists will check your eligibility, prepare the application, and walk you through every step — for free. Create a free account →

Who can apply

Eligibility details aren't on file yet — check the agency source link in the Documents tab for the latest rules.

Geographic eligibility

  • Alabama
  • Alaska
  • Arizona
  • Arkansas
  • California
  • Colorado
  • Connecticut
  • Delaware
  • Florida
  • Georgia
  • Hawaii
  • Idaho
  • Illinois
  • Indiana
  • Iowa
  • Kansas
  • Kentucky
  • Louisiana
  • Maine
  • Maryland
  • Massachusetts
  • Michigan
  • Minnesota
  • Mississippi
  • Missouri
  • Montana
  • Nebraska
  • Nevada
  • New Hampshire
  • New Jersey
  • New Mexico
  • New York
  • North Carolina
  • North Dakota
  • Ohio
  • Oklahoma
  • Oregon
  • Pennsylvania
  • Rhode Island
  • South Carolina
  • South Dakota
  • Tennessee
  • Texas
  • Utah
  • Vermont
  • Virginia
  • Washington
  • West Virginia
  • Wisconsin
  • Wyoming
  • District of Columbia

How to apply

We don't have application instructions on file yet — head straight to the official source.

Apply on agency site
Tip from our team:

Read the agency's eligibility checklist before you start — it's almost always shorter than the full NOFO and will tell you in 90 seconds whether to keep going.

Need help getting in touch with the right agency contact?

Create a free account and our specialists will guide you through the application end-to-end.

Source documents

View on agency site
Canonical NOFO, application packet, and forms
No supplemental documents yet.

Direct downloads (NOFO PDFs, application forms, FAQs) will appear here once our team attaches them. For now, the agency site has the canonical packet.

Citation details

Source systemgrants.gov
Source ID339068
PostedMar 31, 2022

Frequently asked questions

No FAQs yet.

Have a question about this fund? Sign in to open a ticket about this fund.